# Supersaturated Oxygen Therapy as a Treatment for No Reflow

## TL;DR

This paper explores the use of supersaturated oxygen therapy to treat no reflow during heart procedures, showing potential for improving patient outcomes.

## Contribution

The study introduces supersaturated oxygen infusion as a novel adjunct therapy for PCI-related no reflow.

## Key findings

- SSO2 infusion improved symptoms and ejection fraction in a patient with no reflow during PCI.
- SSO2 may offer a promising treatment option for PCI complications with limited current therapies.

## Abstract

No reflow, an interruption in epicardial and microvascular blood flow, during percutaneous coronary intervention (PCI) is associated with adverse outcomes but continues to have limited therapeutic options. We present a case of a patient with multiple comorbidities, multivessel disease and reduced left ventricular function with calcified left anterior descending stenosis who was treated with rotational atherectomy, complicated by slow flow after balloon dilatation. Infusion of supersaturated oxygen (SSO2) into the left main was instituted as an adjunct to PCI, along with pharmacologic vasodilators. Subsequently, there was resolution of the patient’s symptoms and improvement in ejection fraction postprocedurally. The potential role of SSO2 in treating patients with intraoperative no reflow is intriguing, given no reflow’s current limited treatment options and known increased risk of adverse events (major adverse cardiovascular events, cardiogenic shock, and so on). SSO2 may be a promising therapy for PCI complicated by no reflow.